Do You Or A Loved One Have a Cancer Diagnosis?

This Could Be The Most Important Video You've Ever Watched...

Why Are People From Around The World Coming To CHIPSA Hospital For Cancer Treatment?

For over 40 years, patients from all over have been putting their faith in CHIPSA Hospital for their healing journey, not only because of our compelling patient stories but also because of the CHIPSA Approach.

Whereas many facilities get bogged in a single methodology (conventional or alternative) we have always believed that healing from cancer requires a multi-pronged approach. This is why CHIPSA Hospital has been on the forefront of advanced immunotherapy since the late 1970's .

Stage 4 Cancer is a very complicated disease and there is no easy answer for it. This is why the practice here at CHIPSA is focused on maximizing what works for each patient's individual disease and Not  what is the politically correct standard. The question should never be "this vs that?" We focus on what makes the patient's life better!

If you or someone you love would like to see how CHIPSA Hospital can help with a cancer diagnosis please give us a call at 1-888-667-3640. We will schedule a free 30 minute appointment to talk to one of our doctors.

What Does Treatment At CHIPSA Look Like?

As mentioned above, we use an integrative approach when it comes to treating cancer which can include a combination of immunotherapies like checkpoint inhibitors, dendritic cells, natural cell killers, and other innate immune stimulating cancer treatments and some other cancer treatments that are only available at CHIPSA.

Cancer is a very complicated disease that attacks the body in so many different ways, there is no easy answer when it comes to prescribing life saving treatment. 

While we can’t guarantee individual results, we can assure you that we have more experience than any other hospital in North America when it comes to an integrative approach. Our documented expertise in combining the most powerful therapies is the reason why so many others follow our lead. 

We work to help every patient, succeed on their individual road to healing physically, emotionally, and psychologically. 

6 Treatments That Make CHIPSA Unique

Several of the treatments here at CHIPSA have achieved long-term results and similar methods are just under going FDA trials. Below are some of those treatments.

Coley's CPG

Coley Toxin Cancer Treatment

Coley’s Therapy is comprised of a sterile (dead) mixture of gram-positive Streptococcus pyogenes and gram-negative Serratia marcescens bacteria. By introducing the killed bacteria into the body, Dr. Coley could mimic an immune response without the risk of infection. Since cancer cells were formed undetected, the goal is to “unlock” the body’s immune system so that it can identify and kill the cancer cells.

Coley’s CPG therapy is our proprietary blend of CPG-carrying agents that allow the immune system the best chance of creating an anti-tumor immune response. There are currently many clinical trials studying CPG in combination with checkpoint inhibitors.

The belief is that Coley’s CPG turns a tumor from cold to hot, meaning a tumor that previously couldn’t be seen by the immune system is now recognized. Many people think a variation of this treatment could be a staple in all future cancer therapy. CHIPSA has over 38 years of experience working with Coley’s Therapy and we are excited to introduce our new proprietary formulation to our treatment protocols.

  • Coley’s Vaccine therapy is typically administered 2-3 times per week at a dose which achieves a body temperature of between 39.5 °C to 41 °C (approximately 103 °C to 106 °F), while being monitored by qualified medical staff.

  • The exact number of treatments per week may vary depending on each individual patient and other circumstances.
  • About 5-6 hours of treatment are required for each treatment day.
  • Vital signs (blood pressure, heart rate, respiratory rate, temperature) are consistently monitored by professional and experienced medical staff.
  • Coley’s Vaccine has a very long and safe history of use.
  • Generally patients experience improved well being after each treatment.
  • This treatment is ideally used in conjunction with other immunotherapies, such as Gerson Therapy, Dendritic Cells Vaccine, and Autologous Cell Vaccine.

Note: CHIPSA is the only licensed hospital facility treating with CPG Therapy in North America.


Apatone is a proprietary therapy that exhibits synergistic anti-tumor activity and preferentially kills tumor cells by autoschizis. Autoschizis uses a series of self-excisions to induce a type of cell death characterized by exaggerated membrane damage and progressive loss of organelle-free cytoplasm.

This patented technology allows up to 400% more intravenous or oral vitamin C into the cancer cell.

In March of 2008 an FDA Phase I/II Study was done on 17 end stage prostate cancer patients. They were treated with Vitamin C and K3 in a 100:1 ratio under the drug name Apatone.  The Apatone was shown to nearly stop all of the velocity projections of PSA’s. Apatone significantly slowed the cancer; 16 out of 17 patients responded positively.

A sequential study done at MD Anderson Cancer Center in Houston, Texas, combined Apatone with the chemotherapy drug Gemcitabine and showed that the Aptaone by increased the effectiveness of the chemo by over 600% ,with NO extra toxicity.

Since then the ingredients in Apatone have been studied with:

  • Bladder Cancer
  • Glioma Cells
  • Ovarian Cancer
  • Prostate Cancer
  • Cancer Cell Death
  • Oxidative Stress
  • Antitumor Activity
  • Autoschizis
  • Low Dose Chemo
  • Reduction of DNase Activity
  • Checkpoint Inhibitors
  • And more…

Note: CHIPSA is the only hospital in the world approved to use Apatone.



VG-5000 creates a multi-array immune system response against cancers forgotten weak link: The Tumor Endothelium (Membrane that lines the inside of blood vessels of cancer tumors) VG-5000 is a cellular anti-angiogenic cancer product made to stimulate an immune response against the tumor endothelium for solid tumor cancers.

VG-5000 targets seven known proteins and likely many more proteins found on the blood vessels of tumors.

Why do we target the tumor blood vessels?

1. Stopping the tumors mutation stops the ability for the tumor to become resistance to other cancer fighting treatments.

2. Stopping the formation of new blood vessels, angiogenesis, keeps a tumor from growing more than 1 to 2 mm in diameter.

3. The tumor endothelium communicates directly with the immune system which allows the immune system to penetrate into the hypoxic area of the tumor.



Lymphokine-activated killer cells are another powerful weapon in CHIPSA’s arsenal against cancer. They have been shown to destroy both primary and metastatic tumor cells.

LAKs have been studied since the 1980s in the United States. Led by the legendary immunotherapy pioneer Steve Rosenberg, LAKs were combined with high dose IL2. LAKs are white blood cells taken from an aphaeresis draw that has IL2 added to it. If lymphocytes are cultured in the presence of Interleukin-2, it results in the development of effector cells, which are cytotoxic to tumor cells.

It has been shown that lymphocytes, when exposed to Interleukin-2, are capable of lysing fresh, non-cultured cancer cells, both primary and metastatic. LAK cells respond to these lymphokines, particularly IL-2, by lysing tumor cells that were already known to be resistant to NK-cell activity.

The mechanism of LAK cells is distinctive from that of natural killer cells because they can lyse cells that NK cells cannot. LAK cells are also capable of acting against cells that do not display the major histocompatibility complex, as has been shown by the ability to cause lysis in non-immunogenic, allogeneic, and syngeneic tumors. LAK cells are specific to tumor cells and do not display activity against normal cells.

Natural killer cells have been shown to work synergistically with dendritic cells. The combination between LAKs and DCs allows the lysing of tumor cells with the antigen presentation of dendritic cells. We believe this combination is best when it also includes a cytotoxic agent. We achieve this at CHIPSA by combining a low dose of chemotherapy (20% dose) with Apatone (shown to increase effects of some chemotherapies by 600%). This is in conjunction with Coley’s toxins, a healthy diet, and psychological therapy.



Multiple studies focusing on dendritic cell therapies are currently active in the United States and throughout the world.

The first FDA-approved dendritic cell treatment was called Provenge. The U.S. approaches use stored antigens that do not come from the patient, but we believe the very best possible tumor antigen is from the patient’s own body. CHIPSA expands the dendritic cells and gives them back to the patients while using cytotoxic agents like low dose chemotherapy or Apatone.

This personalized version of this cellular product is unique to CHIPSA. Dendritic cells are used by patients who are currently undergoing conventional therapy or want CHIPSA’s full combination approach.



Natural Killer (NK) cells are the immune system’s first defense against disease and infection. NK cells have an amazing ability to seek out and destroy cancer cells. Our goal is to maximize the effects of the NK Cell therapy by using it in combination with our whole body approach.

We take a small blood draw and use the patient’s own NK cells in the lab. Once these cells are trained and expanded, we give them back to the patient with a large army of NK cells ready to fight cancer. Our personalized NK cell therapy is designed to produce a powerful and consistent immune response against cancer.

Some Success Stories From Our Patients

From 2 Weeks Left To Live to FULL Remission…At CHIPSA Hospital!

After being “fired” as a patient by his U.S. oncologist, Stage 4 Cancer patient Thomas Peters sought out other ways to treat his Lymphoma. His story is one that we can all be proud of! 

When Thomas arrived at CHIPSA, he had a tumor in his mouth the size of a baseball and was riddled with swollen lymph nodes in his neck. He had trouble breathing, he had trouble walking, and he had trouble eating. Thomas couldn’t do much of anything. 

Even though his fight is not over, full remission is something to celebrate. This is a beautiful story of one of our amazingly determined patients.

Thank you Tom for being such an inspiration to all and being dedicated to paying it forward with your story!

Ann Fonfa

23 Year Survivor…How Ann Beat Stage 4 Breast Cancer

Ann E. Fonfa received treatment back in 1995 from CHIPSA Hospital and used it as a catalyst. She had a strict focus on Gerson Therapy and never used chemotherapy or radiation during her treatment.

To say she is inspiring is an understatement. She founded The Annie Appleseed Project, a 501(c)(3) non-profit corporation which provides information, education, advocacy, and awareness for people with cancer and their families and friends who are interested in complementary or alternative medicine (CAM) and natural therapies from a patient’s perspective.Ann is a hero to CHIPSA and cancer patients all over the world.

38 Year Stage 4 Melanoma Cancer Survivor Beata Bishop

Beata came to Tijuana, Mexico for 5 weeks in 1980 with stage 4 Melanoma. At the time, she was a reporter for the British Broadcasting Corporation (BBC). She had been told by her oncologist that she had between 6 weeks and 6 months to live when she started researching and looking for other options.

Beata stayed on strict Gerson therapy and was very focused on beating her “terminal” cancer. She says that she was not afraid to die and she felt that her courage was a help through it all. 

Beata says:

“I suffered from early stage diabetes mellitus, incipient osteoarthritis and painful recurrent dental abscesses. Within three weeks at the Gerson clinic in Mexico all three conditions simply vanished, never to return.

Moreover, my surgically mutilated right leg began to grow back some flesh, a process which I watched with jaw-dropping amazement. (Getting rid of the melanoma took much longer, though: the body prefers to deal with the easy bits first.)

Beata is alive today and 96 year old!

Consult With a Doctor Today...

Speak With a CHIPSA Doctor today and receive a treatment plan customized for you.

Medical Director 

Director of Out Patient

Director of Surgery

Surgical Oncologist

Director of Aftercare

Gerson Cancer Dr

 Medical Doctor

CHIPSA Hospital Recruits 3 World ClassCancer Scientists!

CHIPSA Hospital Recruits 3 World Class Cancer Scientists! We are happy to announce the inaugural members of our scientific advisory board. Dr. Franco Marincola, Dr. Philip Kim, Dr. Vijay Mahant.

All have joined CHIPSA as members of our Scientific Advisory Board. All are world-renowned leaders in the field of cancer research, treatment and diagnostics. They have joined forces with CHIPSA to collaborate on early detection and improving treatments. We welcome them to the CHIPSA Tea

Dr. Francesco Marincola - MD

Dr. Marincola is considered one of the world's leading tumor immunologists. He was the chief of the Infectious Disease and Immunogenetics section in the Department of Transfusion Medicine at the Clinical Center of the National Institute of Health in Bethesda. He was also the founder and editor-in-chief of the,Journal of Translational Medicine and ASHI Quarterly, senior editor for the Journal of the American Society for Histocompatibility and Immunogenetics, and editor for a variety of academic journals, including Immunotherapy, Journal of ImmunotherapyJournal of ImmunologyTumoriClinical Cancer ResearchBiological Therapy, Cancer Immunology and Immunotherapy. Additionally, he is a founding member of the Society for Immunotherapy of Cancer.

Dr. Marincola has done extensive research in tumor immunology by developing strategies for studying tumor-host interactions in the context of human genetic polymorphism and cancer heterogeneity. During his tenure as a senior staff scientist with the NCI Surgery Branch, Dr. Marincola investigated the identification of the algorithm responsible for tumor rejection by immune cells in metastatic melanoma. The focus of his research is the optimization of strategies to study clinical material during the conduct of clinical trials. The NIH Immunogenetics Laboratory is recognized nationally and internationally for its cutting edge technologies applied to the study of genetic materials at the genomic, transcriptional, epigenetic and mutational level.

Dr. Vijay Mahant, MS, PhD. 

Dr. Mahant graduated from LUT in the United Kingdom and received his second post-doctorate degree from MD Anderson in Houston TX.  Dr. Mahant is a scientist with over 30 years of experience in immune and molecular diagnostics.  He has held executive positions and serves as the founder/co-founder of diagnostic companies with diverse experiences in research and development including auto genomics, Medi-Lyte and Qualigen. He is the inventor of the “New Generation” ultra-sensitive TSH test for prostate cancer.

Dr. Phillip S. Kim PhD.

Dr. Kim was awarded the Human Genetics Fellowship by the National Institute of Health (NIH) at, Cedar Sinai Medical Center. His research focused on the development of gene-therapy model via hematopoietic-stem cell mediated gene transfer and the development of Geno-dynamics system to investigate gene function.

His work includes: managing planning and execution of technical projects, clinical trials, science and technology communications, research collaborations and KOL (Key Opinion Leader) relationships, and publications.

He is the inventor of the, Immune-Pod, which is positioned to address critical unmet need in oncology clinic by activating patient’s autologous immune cells specific to individual tumors for effective and safe cellular therapy without complex cellular manipulation. Minimally invasive approach using Immuno-Pod maximizes tumor specific immune cell activation by exposing otherwise inaccessible tumor in vivo to contiguous synthetic met ex vivo seamlessly integrated for each patient.

Dr. Kim’s valuable insight at CHIPSA will help guide decisions for precision medicine and specific immune response for all patients.

Your Partner In Your Healing Journey From Cancer.

CHIPSA is committed to supporting your healing in anyway possible.

We have  been fighting cancer and other immunological ailments for more that 40 years. Our staff, including researchers, are always looking for the latest method to combat the cancer disease and integrate them into our protocols. 

We know from our experience of being a hospital providing cancer treatment in Mexico for many years, that cancer is complex and always evolving. There is no 100%  guaranteed way to rid the body  of cancer, every time. What we do know, however, is that CHIPSA has had great success treating many patients that were diagnosed terminal and sent home to "die" in their home country because conventional ideas of medicine failed them.

The CHIPSA Promise

Welcome to The CHIPSA Promise™. We stand behind our patients and want you to be informed. Welcome to hope.

CHIPSA Hospital is an international leader for providing cutting edge integrative medicine. We believe that if you are presented with all of the facts, that you and your loved ones can make the best decision for your health.

Here is our CHIPSA Promise™ to you:

1. All of your pre-approval Doctor Consultations are free… always.

2. We will support you in any decision you make about your health, even if you do not come to CHIPSA. You matter… always.

3. You will receive a written game plan from our Medical Team with clear prices to decide what’s best… always.

4. If we think we can help you, we will tell you. If we do not think we can help you, we will tell you… always.

Don't wait on hope. Act now and see what options you have.

“Courage is not the absence of fear, but rather the judgment that something else is more important than fear.”

Frequently Asked Questions

Why add an FAQ section like this?

How about adding a contact link?

What about exit intent lightboxes?

What questions belong here?

Have you tried a chat widget?

Answer questions, save space.

P.S.: Welcome to the post script section of the page. You can have one or several of these. This part is all about loss aversion. Here is where you can remind your reader that if they don't jump on this opportunity right now they will be missing out.

After the post scripts, use the link below to link to your purchase section or the checkout page.

Copyright - Chipsa Hospital